Organic Revenue Growth*(1) 8% Approximately 4% Free Cash Flow* $1.7 billion ~$1.8 billion | --- | --- | --- | |-----------------------|-------|----------------------------------| | Adjusted EBIT Margin* | 15.1% | 15.6% - 15.9% 50 - 80 bps growth | | Adjusted ETR* 23.7% | | 23% - 25% | | Adjusted EPS* | $3.93 | $4.20 - $4.35 7% - 11% growth | © 2024 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. 13 Investing in Digital for Future Growth Imaging Ultrasound Imaging A ...

In 2023, we published our inaugural sustainability report, highlighting our progress and commitment to corporate responsibility and risk management. Lastly, we introduced 2024 guidance today, which Jay will discuss in greater detail. Our outlook reflects an improved capital equipment landscape. It also reflects continued strength on top of 2 consecutive years of high single-digit organic sales growth. Now, I will pass the call on to Jay to take us through the financials and our business performance. And IÂ' ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

GE HealthCare Technologies (GEHC) reported $5.21 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 5.4%. EPS of $1.18 for the same period compares to $1.31 a year ago.The reported revenue represents a surprise of +2.21% over the Zacks Consensus Estimate of $5.09 billion. With the consensus EPS estimate being $1.07, the EPS surprise was +10.28%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.28%. A quarter ago, it was expected that this medical technology company would post earnings of $0.89 per share when it actually produced earnings of $0.99, delivering a surprise of 11.24%.Over the la ...

GE HealthCare Technologies Inc.’s stock GEHC, -0.68% rose 0.9% early Tuesday, after the company posted better-than-expected profit and revenue for the fourth quarter, offsetting soft guidance for 2024. GE HealthCare, which was spun out of General Electric Co. in January of 2023 and houses its medical device business, posted net income of $403 million, or 88 cents a share, for the quarter, down from $554 million, or $1.21 a share, in the year-earlier period. Adjusted per-share earnings came to $1.18, ahead ...

文章核心观点 - GE HealthCare公司在2023年第四季度和全年取得了强劲的财务业绩,体现了公司专注于精准医疗战略的成功执行 [2][3] - 公司在2023年投入超过10亿美元用于研发,推出了40多项创新产品,同时通过战略收购提升了市场地位,并偿还了10亿美元债务,为未来持续增长奠定了基础 [2][3] - 公司预计2024年有机收入增长约4%,调整后EBIT利润率将达到15.6%-15.9%,调整后每股收益将增长7%-11%,自由现金流约为18亿美元 [21][22][23] 分组1 - 2023年第四季度收入增长5%,其中有机收入增长5% [3] - 第四季度总公司订单增长3%,订单/收入比为1.05倍,显示公司订单持续增长 [4] - 第四季度调整后EBIT利润率为16.1%,与2022年第四季度单独公司调整后EBIT利润率持平 [6] - 第四季度调整后每股收益为1.18美元,较2022年第四季度单独公司调整后每股收益1.06美元增长0.12美元 [7] 分组2 - 2023年全年收入增长7%,有机收入增长8% [13][14] - 全年调整后EBIT利润率为15.1%,较2022年单独公司调整后EBIT利润率14.5%提升60个基点 [16][17] - 2023年全年调整后每股收益为3.93美元,较2022年单独公司调整后每股收益3.38美元增长0.55美元 [18] - 2023年自由现金流约17亿美元,自由现金流转换率为95% [19][20]

债务和财务风险 - 公司在2023年12月31日有约94.42亿美元的债务[334] - 公司的债务水平和履行债务条款的能力可能会对业务、运营结果、现金流和财务状况产生不利影响[333] - 公司可能会发行额外的股票用于收购、资本市场交易或其他用途[341] 法律条款和风险 - 公司存在一些条款可能会阻碍收购并限制股东权力[342] - 公司的章程规定了特定法院为公司与股东之间争议的唯一和专属论坛[345] 市场风险管理 - 公司暴露于市场风险，主要来自利率变动、外汇汇率变动、商品价格和股票价格变动[473] - 公司使用多种技术来管理货币兑换的影响，包括对重要货币敞口进行套期保值[475] - 公司对外汇衍生品合同的潜在价值下降进行了敏感性分析，显示在美元兑其他适用货币汇率下降10%的情况下，可能会减少1300万美元[476] - 利率变动100个基点将使公司年利息支出增加或减少约2200万美元，部分抵消来自现金投资的利息收入变化[480] - 公司通过使用适当的固定利率和浮动利率债务来主要管理利率风险[481] 原材料供应和成本风险 - 公司依赖于氦、碘和稀土矿等某些原材料的供应，这些原材料的全球需求、供应和定价一直波动[482] - 如果某些商品或能源、运输或运输成本增加且公司无法将这些成本转嫁给客户，公司的利润率将受到不利影响[483] 风险管理工具 - 公司可能会不时进行套期保值交易，以减少商品价格波动对收益的影响[486] - 公司持有269百万美元的延期薪酬负债，受股票价格变动风险影响[487] - 了解公司的风险敞口、衍生品使用情况以及这些活动对公司合并财务报表的影响，请参阅《财务工具和公允价值衡量》第13条注释[488]

GE HealthCare Technologies Inc. - GE HealthCare Technologies Inc. 将于2023年2月6日发布第四季度业绩报告[1] - GE HealthCare 完成了医疗业务的分拆，成立了新的 Precision Care 领域的公司[3] - 预计 GE HealthCare 将报告强劲的有机收入增长，受益于平衡的业务表现和新产品推出[3] - GE HealthCare 第四季度2023年的营收预期为50.9亿美元，每股收益预期为1.07美元[9] 影像业务 - 影像业务预计将受益于全球医疗保健提供商持续投资以改善患者护理和生产力[4] 超声波业务 - 超声波业务预计将受益于心血管、一般成像和妇女健康产品的强劲表现[5] 患者护理解决方案业务 - 患者护理解决方案业务预计将受益于有利的销量和定价[6] 制药诊断业务 - 制药诊断业务预计将实现有机收入增长，受益于有利的价格和全球手术程序的恢复[7] 商业表现 - 第四季度的商业表现可能会受到具有挑战性的宏观经济环境和货币风险的影响[8]

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for Novii™+ Wireless Patch Solution. The antepartum and intrapartum maternal and fetal monitor noninvasively measures and displays fetal heart rate, maternal heart rate and uterine activity, so care teams can have a real-time view of patient data. Through its belt-free and wireless design, Novii+ enables mobility and freedom for mothers to support ...